vs

Side-by-side financial comparison of PTC THERAPEUTICS, INC. (PTCT) and Rapid7, Inc. (RPD). Click either name above to swap in a different company.

Rapid7, Inc. is the larger business by last-quarter revenue ($217.4M vs $164.7M, roughly 1.3× PTC THERAPEUTICS, INC.). Rapid7, Inc. runs the higher net margin — 1.4% vs -82.0%, a 83.4% gap on every dollar of revenue. On growth, Rapid7, Inc. posted the faster year-over-year revenue change (0.5% vs -22.7%). Rapid7, Inc. produced more free cash flow last quarter ($36.4M vs $-36.6M). Over the past eight quarters, Rapid7, Inc.'s revenue compounded faster (3.0% CAGR vs -11.5%).

PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.

Rapid7, Inc. is a leading global cybersecurity company that offers a full portfolio of solutions including vulnerability management, threat detection and response, cloud security, and security analytics. It serves enterprises, SMBs, and public sector entities across industries like tech, healthcare, finance, and manufacturing worldwide, helping clients address and mitigate cyber risks efficiently.

PTCT vs RPD — Head-to-Head

Bigger by revenue
RPD
RPD
1.3× larger
RPD
$217.4M
$164.7M
PTCT
Growing faster (revenue YoY)
RPD
RPD
+23.3% gap
RPD
0.5%
-22.7%
PTCT
Higher net margin
RPD
RPD
83.4% more per $
RPD
1.4%
-82.0%
PTCT
More free cash flow
RPD
RPD
$73.1M more FCF
RPD
$36.4M
$-36.6M
PTCT
Faster 2-yr revenue CAGR
RPD
RPD
Annualised
RPD
3.0%
-11.5%
PTCT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PTCT
PTCT
RPD
RPD
Revenue
$164.7M
$217.4M
Net Profit
$-135.0M
$3.1M
Gross Margin
68.9%
Operating Margin
-43.3%
1.0%
Net Margin
-82.0%
1.4%
Revenue YoY
-22.7%
0.5%
Net Profit YoY
-104.8%
44.1%
EPS (diluted)
$-1.63
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PTCT
PTCT
RPD
RPD
Q4 25
$164.7M
$217.4M
Q3 25
$211.0M
$218.0M
Q2 25
$178.9M
$214.2M
Q1 25
$1.2B
$210.3M
Q4 24
$213.2M
$216.3M
Q3 24
$196.8M
$214.7M
Q2 24
$186.7M
$208.0M
Q1 24
$210.1M
$205.1M
Net Profit
PTCT
PTCT
RPD
RPD
Q4 25
$-135.0M
$3.1M
Q3 25
$15.9M
$9.8M
Q2 25
$-64.8M
$8.3M
Q1 25
$866.6M
$2.1M
Q4 24
$-65.9M
$2.2M
Q3 24
$-106.7M
$15.4M
Q2 24
$-99.2M
$6.5M
Q1 24
$-91.6M
$1.4M
Gross Margin
PTCT
PTCT
RPD
RPD
Q4 25
68.9%
Q3 25
70.2%
Q2 25
70.6%
Q1 25
71.7%
Q4 24
69.5%
Q3 24
70.6%
Q2 24
70.7%
Q1 24
70.3%
Operating Margin
PTCT
PTCT
RPD
RPD
Q4 25
-43.3%
1.0%
Q3 25
1.4%
2.7%
Q2 25
-19.5%
1.6%
Q1 25
82.5%
-0.0%
Q4 24
-76.2%
3.4%
Q3 24
-27.7%
6.0%
Q2 24
-21.5%
2.5%
Q1 24
-21.6%
4.7%
Net Margin
PTCT
PTCT
RPD
RPD
Q4 25
-82.0%
1.4%
Q3 25
7.5%
4.5%
Q2 25
-36.3%
3.9%
Q1 25
73.7%
1.0%
Q4 24
-30.9%
1.0%
Q3 24
-54.2%
7.2%
Q2 24
-53.1%
3.1%
Q1 24
-43.6%
0.7%
EPS (diluted)
PTCT
PTCT
RPD
RPD
Q4 25
$-1.63
$0.05
Q3 25
$0.20
$0.15
Q2 25
$-0.83
$0.13
Q1 25
$10.04
$0.03
Q4 24
$-0.85
$0.08
Q3 24
$-1.39
$0.21
Q2 24
$-1.29
$0.09
Q1 24
$-1.20
$0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PTCT
PTCT
RPD
RPD
Cash + ST InvestmentsLiquidity on hand
$1.9B
$474.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$-205.3M
$154.7M
Total Assets
$2.9B
$1.7B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PTCT
PTCT
RPD
RPD
Q4 25
$1.9B
$474.7M
Q3 25
$1.7B
$407.1M
Q2 25
$2.0B
$511.7M
Q1 25
$2.0B
$493.5M
Q4 24
$1.1B
$521.7M
Q3 24
$1.0B
$443.7M
Q2 24
$1.1B
$442.6M
Q1 24
$884.8M
$411.7M
Stockholders' Equity
PTCT
PTCT
RPD
RPD
Q4 25
$-205.3M
$154.7M
Q3 25
$-155.8M
$127.2M
Q2 25
$-206.5M
$90.4M
Q1 25
$-185.8M
$52.7M
Q4 24
$-1.1B
$17.7M
Q3 24
$-1.1B
$-5.1M
Q2 24
$-980.2M
$-52.6M
Q1 24
$-893.9M
$-86.4M
Total Assets
PTCT
PTCT
RPD
RPD
Q4 25
$2.9B
$1.7B
Q3 25
$2.6B
$1.7B
Q2 25
$2.6B
$1.6B
Q1 25
$2.7B
$1.6B
Q4 24
$1.7B
$1.7B
Q3 24
$1.8B
$1.6B
Q2 24
$1.9B
$1.5B
Q1 24
$1.8B
$1.5B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PTCT
PTCT
RPD
RPD
Operating Cash FlowLast quarter
$-34.3M
$37.6M
Free Cash FlowOCF − Capex
$-36.6M
$36.4M
FCF MarginFCF / Revenue
-22.3%
16.8%
Capex IntensityCapex / Revenue
1.4%
0.5%
Cash ConversionOCF / Net Profit
12.01×
TTM Free Cash FlowTrailing 4 quarters
$702.3M
$146.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PTCT
PTCT
RPD
RPD
Q4 25
$-34.3M
$37.6M
Q3 25
$-66.3M
$39.0M
Q2 25
$-58.3M
$47.5M
Q1 25
$870.1M
$29.8M
Q4 24
$-30.0M
$63.8M
Q3 24
$-77.0M
$44.0M
Q2 24
$-71.5M
$32.9M
Q1 24
$70.8M
$31.1M
Free Cash Flow
PTCT
PTCT
RPD
RPD
Q4 25
$-36.6M
$36.4M
Q3 25
$-69.7M
$34.8M
Q2 25
$-59.6M
$46.6M
Q1 25
$868.4M
$28.4M
Q4 24
$-33.8M
$62.6M
Q3 24
$-77.5M
$42.6M
Q2 24
$-78.8M
$32.6M
Q1 24
$61.2M
$30.4M
FCF Margin
PTCT
PTCT
RPD
RPD
Q4 25
-22.3%
16.8%
Q3 25
-33.1%
16.0%
Q2 25
-33.3%
21.8%
Q1 25
73.8%
13.5%
Q4 24
-15.8%
28.9%
Q3 24
-39.4%
19.9%
Q2 24
-42.2%
15.7%
Q1 24
29.1%
14.8%
Capex Intensity
PTCT
PTCT
RPD
RPD
Q4 25
1.4%
0.5%
Q3 25
1.6%
1.9%
Q2 25
0.7%
0.4%
Q1 25
0.1%
0.6%
Q4 24
1.8%
0.5%
Q3 24
0.3%
0.6%
Q2 24
4.0%
0.1%
Q1 24
4.6%
0.3%
Cash Conversion
PTCT
PTCT
RPD
RPD
Q4 25
12.01×
Q3 25
-4.17×
3.97×
Q2 25
5.70×
Q1 25
1.00×
14.14×
Q4 24
29.36×
Q3 24
2.85×
Q2 24
5.03×
Q1 24
22.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PTCT
PTCT

Segment breakdown not available.

RPD
RPD

Products$209.1M96%
Services$8.2M4%

Related Comparisons